Another study showed that CCL2, CCL3 and CCL5 were significantly higher in serum of patients with SSc than in controls and therapy with prostaglandins down-regulated CCL2 and CCL5, suggesting an effect of vasodilator therapy on inflammation in SSc [48]. This evidence concerns the gene CCL5 and systemic sclerosis.